New Drug Application Updates, Appointments, Partnership Programs, and Stock Movements - Research Report on Amarin, Oramed Pharmaceuticals, Synta Pharmaceuticals, Healthways and AMN Healthcare Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, December 25, 2013 NEW YORK, December 25, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Amarin Corporation plc (NASDAQ: AMRN), Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Healthways Inc. (NASDAQ: HWAY), and AMN Healthcare Services Inc. (NYSE: AHS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Amarin Corporation plc Research Report On December 20, 2013, Amarin Corporation plc (Amarin) announced that it has been notified by the U.S. Food and Drug Administration (FDA) that the FDA does not expect to take action on the Company's supplemental new drug application (sNDA) for the proposed ANCHOR indication labeling expansion for Vascepa® (icosapent ethyl) capsules on the December 20, 2013, Prescription Drug User Fee Act (PDUFA) goal date since the Company's request to re-instate the ANCHOR Special Protocol Assessment (SPA) agreement is under consideration with the FDA. Amarin added that no new PDUFA date has been decided. The Company also stated that FDA intends to complete its review of Amarin's request to re-instate the ANCHOR SPA agreement and to inform its decision to Amarin before January 15, 2014. In another release dated December 16, 2013, Amarin announced the appointment of current President, John F. Thero, as President and CEO of the Company, along with his appointment to the Board of Directors, effective January 1, 2014. The Company further informed that Joseph S. Zakrzewksi will retire as CEO and Chairman, and Lars Ekman, MD, PhD, current Lead Independent Director, will become Chairman of the Board, effective January 1, 2014. The Full Research Report on Amarin Corporation plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/7cf9_AMRN -- Oramed Pharmaceuticals Inc. Research Report On December 20, 2013, Oramed Pharmaceuticals Inc.'s (Oramed Pharmaceuticals) stock rallied 48.95%, closing the day at $10.65. Over the past three trading days, the Company's stock surged 53.24%, compared to the Dow Jones Industrial Average, which advanced 2.18% during the same three day trading period. The Full Research Report on Oramed Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/c199_ORMP -- Synta Pharmaceuticals Corp. Research Report On December 20, 2013, Synta Pharmaceuticals Corp. (Synta) announced that it has appointed Steven Bernitz as Senior Vice President, Corporate Development. The Company stated that Mr. Bernitz has over 20 years of experience in corporate strategy, business leadership and transactional experience in life sciences, and was a General Partner and Head of the BioPharma Practice at Extera Partners, before joining Synta. Commenting on the appointment, Safi Bahcall, President and CEO, Synta, stated, "Steve has tremendous deal experience, as is clear from his track record, which will be valuable in realizing the potential of both our ganetespib and HDC programs. His wealth of diverse business experiences and insights make him an excellent addition to our executive team, as we manage a growing pipeline and an increasing number of important strategic and operational choices." The Full Research Report on Synta Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/8ecc_SNTA -- Healthways Inc. Research Report On December 17, 2013, Healthways Inc. (Healthways) reported that Freedom Health and Optimum Healthcare have partnered with the Company to offer the award-winning SilverSneakers® Fitness Program to eligible Medicare Advantage members through 2016. According to the Company, SilverSneakers is a leading exercise program designed exclusively for older adults, and has proven to reduce healthcare costs and improve physical, cognitive and social well-being of its members. Healthways stated that SilverSneakers will be available to eligible Medicare Advantage members of Freedom Health and Optimum HealthCare plans in Florida, starting January 1, 2014. Commenting on the release, Ben R. Leedle, Jr., Healthways President and CEO, stated, "By offering SilverSneakers, Freedom Health and Optimum HealthCare are fulfilling the needs of their eligible older-adult Medicare Advantage members by promoting wellness, embracing innovation and pursuing excellence in the delivery of healthcare. We look forward to partnering with Freedom Health and Optimum HealthCare in providing this time-tested, proven program to their members and helping them realize higher well-being and greater quality of life." The Full Research Report on Healthways Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/76fd_HWAY -- AMN Healthcare Services Inc. Research Report On December 20, 2013, AMN Healthcare Services Inc.'s (AMN Healthcare) stock went up by 6.54%, closing at $14.49. For the past three trading days, the Company's stock gained 5.00%, compared to the Dow Jones Industrial Average, which moved up 2.18% over the same three day trading period. The Full Research Report on AMN Healthcare Services Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/b6d6_AHS ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
New Drug Application Updates, Appointments, Partnership Programs, and Stock Movements - Research Report on Amarin, Oramed
Press spacebar to pause and continue. Press esc to stop.